6prz - Revision history

OCA at 07:34, 11 October 2023

OCA — Wed, 11 Oct 2023 07:34:33 GMT

←Older revision		Revision as of 07:34, 11 October 2023
Line 3:		Line 3:
	<StructureSection load='6prz' size='340' side='right'caption='[[6prz]], [[Resolution\|resolution]] 2.80Å' scene=''>		<StructureSection load='6prz' size='340' side='right'caption='[[6prz]], [[Resolution\|resolution]] 2.80Å' scene=''>
	== Structural highlights ==		== Structural highlights ==
-	<table><tr><td colspan='2'>[[6prz]] is a 1 chain structure with sequence from [~~http~~://en.wikipedia.org/wiki/~~Human Human~~]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=6PRZ OCA]. For a <b>guided tour on the structure components</b> use [~~http~~://~~oca~~.~~weizmann.ac.il/oca-docs~~/fgij/fg.htm?mol=6PRZ FirstGlance]. <br>	+	<table><tr><td colspan='2'>[[6prz]] is a 1 chain structure with sequence from [https://en.wikipedia.org/wiki/Escherichia_virus_T4 Escherichia virus T4] and [https://en.wikipedia.org/wiki/Homo_sapiens Homo sapiens]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=6PRZ OCA]. For a <b>guided tour on the structure components</b> use [https://proteopedia.org/fgij/fg.htm?mol=6PRZ FirstGlance]. <br>
-	</td></tr><tr id='ligand'><td class="sblockLbl"><b>[[Ligand\|Ligands:]]</b></td><td class="sblockDat"><scene name='pdbligand=CLR:CHOLESTEROL'>CLR</scene>, <scene name='pdbligand=JTZ:(2S)-1-[(1-METHYLETHYL)AMINO]-3-(2-PROP-2-EN-1-YLPHENOXY)PROPAN-2-OL'>JTZ</scene>, <scene name='pdbligand=OLA:OLEIC+ACID'>OLA</scene>, <scene name='pdbligand=OLC:(2R)-2,3-DIHYDROXYPROPYL+(9Z)-OCTADEC-9-ENOATE'>OLC</scene>, <scene name='pdbligand=SO4:SULFATE+ION'>SO4</scene>~~</td></tr>~~	+	</td></tr><tr id='method'><td class="sblockLbl"><b>[[Empirical_models\|Method:]]</b></td><td class="sblockDat" id="methodDat">X-ray diffraction, [[Resolution\|Resolution]] 2.8Å</td></tr>
-	~~<tr id='gene'><td class="sblockLbl"><b>[[Gene\|Gene:]]</b></td><td class="sblockDat">ADRB2, ADRB2R, B2AR ([http://www.ncbi.nlm.nih.gov/Taxonomy/Browser/wwwtax.cgi?mode=Info&srchmode=5&id=9606 HUMAN])~~</td></tr>	+	<tr id='ligand'><td class="sblockLbl"><b>[[Ligand\|Ligands:]]</b></td><td class="sblockDat" id="ligandDat"><scene name='pdbligand=CLR:CHOLESTEROL'>CLR</scene>, <scene name='pdbligand=JTZ:(2S)-1-[(1-METHYLETHYL)AMINO]-3-(2-PROP-2-EN-1-YLPHENOXY)PROPAN-2-OL'>JTZ</scene>, <scene name='pdbligand=OLA:OLEIC+ACID'>OLA</scene>, <scene name='pdbligand=OLC:(2R)-2,3-DIHYDROXYPROPYL+(9Z)-OCTADEC-9-ENOATE'>OLC</scene>, <scene name='pdbligand=SO4:SULFATE+ION'>SO4</scene></td></tr>
-	<tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[~~http~~://~~oca~~.~~weizmann.ac.il/oca-docs~~/fgij/fg.htm?mol=6prz FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=6prz OCA], [~~http~~://pdbe.org/6prz PDBe], [~~http~~://www.rcsb.org/pdb/explore.do?structureId=6prz RCSB], [~~http~~://www.ebi.ac.uk/pdbsum/6prz PDBsum], [~~http~~://prosat.h-its.org/prosat/prosatexe?pdbcode=6prz ProSAT]</span></td></tr>	+	<tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[https://proteopedia.org/fgij/fg.htm?mol=6prz FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=6prz OCA], [https://pdbe.org/6prz PDBe], [https://www.rcsb.org/pdb/explore.do?structureId=6prz RCSB], [https://www.ebi.ac.uk/pdbsum/6prz PDBsum], [https://prosat.h-its.org/prosat/prosatexe?pdbcode=6prz ProSAT]</span></td></tr>
	</table>		</table>
	== Function ==		== Function ==
-	[[~~http~~://www.uniprot.org/uniprot/ADRB2_HUMAN ADRB2_HUMAN]] Beta-adrenergic receptors mediate the catecholamine-induced activation of adenylate cyclase through the action of G proteins. The beta-2-adrenergic receptor binds epinephrine with an approximately 30-fold greater affinity than it does norepinephrine.	+	[https://www.uniprot.org/uniprot/D9IEF7_BPT4 D9IEF7_BPT4] [https://www.uniprot.org/uniprot/ADRB2_HUMAN ADRB2_HUMAN] Beta-adrenergic receptors mediate the catecholamine-induced activation of adenylate cyclase through the action of G proteins. The beta-2-adrenergic receptor binds epinephrine with an approximately 30-fold greater affinity than it does norepinephrine.
	<div style="background-color:#fffaf0;">		<div style="background-color:#fffaf0;">
	== Publication Abstract from PubMed ==		== Publication Abstract from PubMed ==
Line 19:		Line 19:
	</div>		</div>
	<div class="pdbe-citations 6prz" style="background-color:#fffaf0;"></div>		<div class="pdbe-citations 6prz" style="background-color:#fffaf0;"></div>
		+
		+	==See Also==
		+	*[[Adrenergic receptor 3D structures\|Adrenergic receptor 3D structures]]
		+	*[[Lysozyme 3D structures\|Lysozyme 3D structures]]
	== References ==		== References ==
	<references/>		<references/>
	__TOC__		__TOC__
	</StructureSection>		</StructureSection>
-	[[Category: ~~Human~~]]	+	[[Category: Escherichia virus T4]]
		+	[[Category: Homo sapiens]]
	[[Category: Large Structures]]		[[Category: Large Structures]]
-	[[Category: Batyuk, A]]	+	[[Category: Batyuk A]]
-	[[Category: Cherezov, C]]	+	[[Category: Cherezov C]]
-	[[Category: Gati, C]]	+	[[Category: Gati C]]
-	[[Category: Han~~, G W~~]]	+	[[Category: Han GW]]
-	[[Category: Ishchenko, A]]	+	[[Category: Ishchenko A]]
-	[[Category: Iwata, S]]	+	[[Category: Iwata S]]
-	[[Category: Joti, Y]]	+	[[Category: Joti Y]]
-	[[Category: Li, C]]	+	[[Category: Li C]]
-	[[Category: Liu, W]]	+	[[Category: Liu W]]
-	[[Category: Moraes, I]]	+	[[Category: Moraes I]]
-	[[Category: Nakane, T]]	+	[[Category: Nakane T]]
-	[[Category: Nango, E]]	+	[[Category: Nango E]]
-	[[Category: Shiriaeva, A]]	+	[[Category: Shiriaeva A]]
-	[[Category: Stauch, B]]	+	[[Category: Stauch B]]
-	[[Category: Tanaka, R]]	+	[[Category: Tanaka R]]
-	[[Category: Tono, K]]	+	[[Category: Tono K]]
-	[[Category: Weierstall, U]]	+	[[Category: Weierstall U]]
-	[[Category: Zatsepin~~, N A]]~~	+	[[Category: Zatsepin NA]]
-	~~[[Category: Alprenolol]]~~	+
-	~~[[Category: B2ar]]~~	+
-	~~[[Category: Beta2ar]]~~	+
-	~~[[Category: Complex-lcp method]]~~	+
-	~~[[Category: Drug design]]~~	+
-	~~[[Category: Gpcr]]~~	+
-	~~[[Category: Lcp-sfx]]~~	+
-	~~[[Category: Ligand exchange]]~~	+
-	~~[[Category: Membrane protein]]~~	+
-	~~[[Category: Sbdd]]~~	+
-	~~[[Category: Xfel~~]]	+

OCA at 13:07, 25 December 2019

OCA — Wed, 25 Dec 2019 13:07:47 GMT

←Older revision		Revision as of 13:07, 25 December 2019
Line 3:		Line 3:
	<StructureSection load='6prz' size='340' side='right'caption='[[6prz]], [[Resolution\|resolution]] 2.80Å' scene=''>		<StructureSection load='6prz' size='340' side='right'caption='[[6prz]], [[Resolution\|resolution]] 2.80Å' scene=''>
	== Structural highlights ==		== Structural highlights ==
-	<table><tr><td colspan='2'>[[6prz]] is a 1 chain structure. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=6PRZ OCA]. For a <b>guided tour on the structure components</b> use [http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=6PRZ FirstGlance]. <br>	+	<table><tr><td colspan='2'>[[6prz]] is a 1 chain structure with sequence from [http://en.wikipedia.org/wiki/Human Human]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=6PRZ OCA]. For a <b>guided tour on the structure components</b> use [http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=6PRZ FirstGlance]. <br>
	</td></tr><tr id='ligand'><td class="sblockLbl"><b>[[Ligand\|Ligands:]]</b></td><td class="sblockDat"><scene name='pdbligand=CLR:CHOLESTEROL'>CLR</scene>, <scene name='pdbligand=JTZ:(2S)-1-[(1-METHYLETHYL)AMINO]-3-(2-PROP-2-EN-1-YLPHENOXY)PROPAN-2-OL'>JTZ</scene>, <scene name='pdbligand=OLA:OLEIC+ACID'>OLA</scene>, <scene name='pdbligand=OLC:(2R)-2,3-DIHYDROXYPROPYL+(9Z)-OCTADEC-9-ENOATE'>OLC</scene>, <scene name='pdbligand=SO4:SULFATE+ION'>SO4</scene></td></tr>		</td></tr><tr id='ligand'><td class="sblockLbl"><b>[[Ligand\|Ligands:]]</b></td><td class="sblockDat"><scene name='pdbligand=CLR:CHOLESTEROL'>CLR</scene>, <scene name='pdbligand=JTZ:(2S)-1-[(1-METHYLETHYL)AMINO]-3-(2-PROP-2-EN-1-YLPHENOXY)PROPAN-2-OL'>JTZ</scene>, <scene name='pdbligand=OLA:OLEIC+ACID'>OLA</scene>, <scene name='pdbligand=OLC:(2R)-2,3-DIHYDROXYPROPYL+(9Z)-OCTADEC-9-ENOATE'>OLC</scene>, <scene name='pdbligand=SO4:SULFATE+ION'>SO4</scene></td></tr>
		+	<tr id='gene'><td class="sblockLbl"><b>[[Gene\|Gene:]]</b></td><td class="sblockDat">ADRB2, ADRB2R, B2AR ([http://www.ncbi.nlm.nih.gov/Taxonomy/Browser/wwwtax.cgi?mode=Info&srchmode=5&id=9606 HUMAN])</td></tr>
	<tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=6prz FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=6prz OCA], [http://pdbe.org/6prz PDBe], [http://www.rcsb.org/pdb/explore.do?structureId=6prz RCSB], [http://www.ebi.ac.uk/pdbsum/6prz PDBsum], [http://prosat.h-its.org/prosat/prosatexe?pdbcode=6prz ProSAT]</span></td></tr>		<tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=6prz FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=6prz OCA], [http://pdbe.org/6prz PDBe], [http://www.rcsb.org/pdb/explore.do?structureId=6prz RCSB], [http://www.ebi.ac.uk/pdbsum/6prz PDBsum], [http://prosat.h-its.org/prosat/prosatexe?pdbcode=6prz ProSAT]</span></td></tr>
	</table>		</table>
	== Function ==		== Function ==
	[[http://www.uniprot.org/uniprot/ADRB2_HUMAN ADRB2_HUMAN]] Beta-adrenergic receptors mediate the catecholamine-induced activation of adenylate cyclase through the action of G proteins. The beta-2-adrenergic receptor binds epinephrine with an approximately 30-fold greater affinity than it does norepinephrine.		[[http://www.uniprot.org/uniprot/ADRB2_HUMAN ADRB2_HUMAN]] Beta-adrenergic receptors mediate the catecholamine-induced activation of adenylate cyclase through the action of G proteins. The beta-2-adrenergic receptor binds epinephrine with an approximately 30-fold greater affinity than it does norepinephrine.
		+	<div style="background-color:#fffaf0;">
		+	== Publication Abstract from PubMed ==
		+	Rational structure-based drug design (SBDD) relies on the availability of a large number of co-crystal structures to map the ligand-binding pocket of the target protein and use this information for lead-compound optimization via an iterative process. While SBDD has proven successful for many drug-discovery projects, its application to G protein-coupled receptors (GPCRs) has been limited owing to extreme difficulties with their crystallization. Here, a method is presented for the rapid determination of multiple co-crystal structures for a target GPCR in complex with various ligands, taking advantage of the serial femtosecond crystallography approach, which obviates the need for large crystals and requires only submilligram quantities of purified protein. The method was applied to the human beta2-adrenergic receptor, resulting in eight room-temperature co-crystal structures with six different ligands, including previously unreported structures with carvedilol and propranolol. The generality of the proposed method was tested with three other receptors. This approach has the potential to enable SBDD for GPCRs and other difficult-to-crystallize membrane proteins.
		+
		+	Toward G protein-coupled receptor structure-based drug design using X-ray lasers.,Ishchenko A, Stauch B, Han GW, Batyuk A, Shiriaeva A, Li C, Zatsepin N, Weierstall U, Liu W, Nango E, Nakane T, Tanaka R, Tono K, Joti Y, Iwata S, Moraes I, Gati C, Cherezov V IUCrJ. 2019 Oct 24;6(Pt 6):1106-1119. doi: 10.1107/S2052252519013137. eCollection, 2019 Nov 1. PMID:31709066<ref>PMID:31709066</ref>
		+
		+	From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.<br>
		+	</div>
		+	<div class="pdbe-citations 6prz" style="background-color:#fffaf0;"></div>
		+	== References ==
		+	<references/>
	__TOC__		__TOC__
	</StructureSection>		</StructureSection>
		+	[[Category: Human]]
	[[Category: Large Structures]]		[[Category: Large Structures]]
	[[Category: Batyuk, A]]		[[Category: Batyuk, A]]

OCA at 11:07, 13 November 2019

OCA — Wed, 13 Nov 2019 11:07:48 GMT

←Older revision		Revision as of 11:07, 13 November 2019
Line 1:		Line 1:
-	'''Unreleased structure'''

-	~~The entry~~ 6prz is ~~ON HOLD until Paper Publication~~	+	==XFEL beta2 AR structure by ligand exchange from Alprenolol to Alprenolol.==
-		+	<StructureSection load='6prz' size='340' side='right'caption='[[6prz]], [[Resolution\|resolution]] 2.80Å' scene=''>
-	~~Authors~~:	+	== Structural highlights ==
-		+	<table><tr><td colspan='2'>[[6prz]] is a 1 chain structure. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=6PRZ OCA]. For a <b>guided tour on the structure components</b> use [http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=6PRZ FirstGlance]. <br>
-	~~Description~~:	+	</td></tr><tr id='ligand'><td class="sblockLbl"><b>[[Ligand\|Ligands:]]</b></td><td class="sblockDat"><scene name='pdbligand=CLR:CHOLESTEROL'>CLR</scene>, <scene name='pdbligand=JTZ:(2S)-1-[(1-METHYLETHYL)AMINO]-3-(2-PROP-2-EN-1-YLPHENOXY)PROPAN-2-OL'>JTZ</scene>, <scene name='pdbligand=OLA:OLEIC+ACID'>OLA</scene>, <scene name='pdbligand=OLC:(2R)-2,3-DIHYDROXYPROPYL+(9Z)-OCTADEC-9-ENOATE'>OLC</scene>, <scene name='pdbligand=SO4:SULFATE+ION'>SO4</scene></td></tr>
-	[[Category: ~~Unreleased~~ Structures]]	+	<tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=6prz FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=6prz OCA], [http://pdbe.org/6prz PDBe], [http://www.rcsb.org/pdb/explore.do?structureId=6prz RCSB], [http://www.ebi.ac.uk/pdbsum/6prz PDBsum], [http://prosat.h-its.org/prosat/prosatexe?pdbcode=6prz ProSAT]</span></td></tr>
		+	</table>
		+	== Function ==
		+	[[http://www.uniprot.org/uniprot/ADRB2_HUMAN ADRB2_HUMAN]] Beta-adrenergic receptors mediate the catecholamine-induced activation of adenylate cyclase through the action of G proteins. The beta-2-adrenergic receptor binds epinephrine with an approximately 30-fold greater affinity than it does norepinephrine.
		+	__TOC__
		+	</StructureSection>
		+	[[Category: Large Structures]]
		+	[[Category: Batyuk, A]]
		+	[[Category: Cherezov, C]]
		+	[[Category: Gati, C]]
		+	[[Category: Han, G W]]
		+	[[Category: Ishchenko, A]]
		+	[[Category: Iwata, S]]
		+	[[Category: Joti, Y]]
		+	[[Category: Li, C]]
		+	[[Category: Liu, W]]
		+	[[Category: Moraes, I]]
		+	[[Category: Nakane, T]]
		+	[[Category: Nango, E]]
		+	[[Category: Shiriaeva, A]]
		+	[[Category: Stauch, B]]
		+	[[Category: Tanaka, R]]
		+	[[Category: Tono, K]]
		+	[[Category: Weierstall, U]]
		+	[[Category: Zatsepin, N A]]
		+	[[Category: Alprenolol]]
		+	[[Category: B2ar]]
		+	[[Category: Beta2ar]]
		+	[[Category: Complex-lcp method]]
		+	[[Category: Drug design]]
		+	[[Category: Gpcr]]
		+	[[Category: Lcp-sfx]]
		+	[[Category: Ligand exchange]]
		+	[[Category: Membrane protein]]
		+	[[Category: Sbdd]]
		+	[[Category: Xfel]]

OCA at 04:43, 31 July 2019

OCA — Wed, 31 Jul 2019 04:43:22 GMT

←Older revision		Revision as of 04:43, 31 July 2019
Line 1:		Line 1:
	'''Unreleased structure'''		'''Unreleased structure'''

-	The entry 6prz is ON HOLD	+	The entry 6prz is ON HOLD until Paper Publication

	Authors:		Authors:

OCA: Protected "6prz" [edit=sysop:move=sysop]

OCA — Wed, 17 Jul 2019 09:11:30 GMT

Protected "6prz" [edit=sysop:move=sysop]

←Older revision

Revision as of 09:11, 17 July 2019

OCA: New page: '''Unreleased structure''' The entry 6prz is ON HOLD Authors: Description: Category: Unreleased Structures

OCA — Wed, 17 Jul 2019 09:11:28 GMT

New page: '''Unreleased structure''' The entry 6prz is ON HOLD Authors: Description: Category: Unreleased Structures

New page

'''Unreleased structure'''

The entry 6prz is ON HOLD

Authors:

Description:
[[Category: Unreleased Structures]]